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Objective. Permanent interstitial brachytherapy is an ideal yet underutilized treatment modality for accessi-
ble, small volume gynecological malignancies. We present early clinical results utilizing a new permanent
isotope, Cs-131.
Methods. A retrospective reviewwas performed evaluating patients treated with Cs-131 permanent intersti-
tial radiation at our institution from July 2011 through June 2013. Doses were most commonly prescribed and
calculated to a depth of 5mmusing Paterson-Parker planar implant rules for Au-198. This activity was converted
to air-kerma strength (U). A conversion factor of 1.1 was applied based on RBE calculations, clinical observation
and experience.
Results. 14 patients were identiﬁed among whom 17 Cs-131 implants were performed. Seven patients were
implanted as sole therapy, and a median dose of 50 Gy was delivered. Ten implants were performed as boost
within a more extensive radiation treatment plan. In these patients, a median implant dose of 27.5 Gy was
used and the median total dose delivered in combination was 78.25 Gy. After a median follow up of 12 months,
the actuarial local control rate was 84.4%. A very low level of grade 1–3 reactions was observed with no ﬁstula
formations or other severe side effects.
Conclusions. Permanent interstitial brachytherapywith Cs-131waswell toleratedwith favorable early results
compared to other series. Cs-131 has multiple favorable properties, including minimal radiation exposure to
treating staff, and should be considered as a therapeutic option in appropriately selected patients. Amethodology
for dose prescription, calculation of radioactivity required and distribution of the isotope is also presented.© 2014 The Authors. Published by Elsevier Inc.Open access under CC BY license. Introduction
Gynecologic cancers account for the fourth highest incidence and
mortality amongwomen in the USwith an estimated 88,750 cases diag-
nosed in 2012 and an estimated 29,520 deaths [1]. The standard of care
for gynecologic malignancies frequently entails pelvic radiation therapy
(RT) either in the deﬁnitive or adjuvant setting in some combination
with brachytherapy, surgery and/or chemotherapy. The close proximitypital, University of Kentucky,
0293, USA. Fax: +1 859 257
.Open access under CC BY license. of gynecologic tumors to radiation-sensitive organs, such as the rectum
and small bowel, limits the cumulative RT dose that can be delivered
due to the potential for late toxicity. As a result, some consider a single
course of RT to preclude the possibility for re-irradiation, thereby sub-
jecting patients to radical surgeries or palliative therapies, as the only
treatment approaches in the recurrent setting [2,3]. Permanent intersti-
tial brachytherapy represents an ideal and proven treatment strategy to
curatively manage accessible small volume gynecologic malignancies
when the goal is to achieve a high cumulative radiation dosewhilemin-
imizing adjacent normal tissue toxicity [4–10].
The widespread application of permanent interstitial brachytherapy
remains limited in gynecologicmalignancies despite numerous success-
ful reports employing Au-198 implants. This is perhaps due to the lack
269C.E. Wooten et al. / Gynecologic Oncology 133 (2014) 268–273of familiarity and experience with permanent implantation techniques
and/or concerns about radiation exposure to personnel [8,11]. However,
recent success with safer ultra low-dose-rate (ULDR) isotopes has re-
stimulated interest in permanent interstitial brachytherapy and
prompted our interest for use in gynecologic malignancies. Cs-131 has
multiple favorable dosimetric properties for interstitial brachytherapy
[12-14]. The mean energy of Cs-131 is lower and the half-life is longer
than Au-198, which translates to a decrease in the exposure to radiation
oncologists, staff and patient families. With a half-life of 9.7 days,
Cs-131 has a relatively high initial dose rate in comparison to I-125
and Pd-103 for equal prescription doses. Cs-131 is a favorable isotope
for use across a wide range of tumors and its dose distribution proper-
ties facilitate easy calculation and use in the clinic [14,15]. An advantage
of Au-198 has been the 1-to-1 conversion between brachytherapy and
conventionally fractionated external beam prescription doses, thus
making prescriptions relatively simple. Given the slightly longer half-
life of Cs-131 compared to Au-198, it was expected that a conversion
factor for dose equivalence would be reasonably close to, but slightly
higher than, 1.0.
In this retrospective series, which includes the ﬁrst reported case of
Cs-131 for a gynecologic malignancy, we present our experience utiliz-
ing Cs-131 permanent interstitial implants for small volume gynecologic
malignancies in both the primary and recurrent settings. This favorable
early data supports treatment with Cs-131 permanent interstitial im-
plants to small volume gynecologic malignancies. Cs-131 implants are
safe, well tolerated, and provide local control rates similar to those re-
ported by previous studies using Au-198, and will often result in cure
in appropriately selected patients.
Methods
Patient population
An IRB approved retrospective review of all patients treated with
Cs-131 permanent interstitial radiation for gynecologic malignancies
from July 2011 through June 2013wasperformed. All patients had path-
ologically proven cancer thatwas readily visible and accessible by pelvic
examination and underwent complete workup, including complete
physical exams by both the treating radiation oncologist and a gyneco-
logic oncologist. Patients underwent radiographic imaging with CT
and/or MRI so as to assess the extent of disease.
Dosimetric modeling
Cs-131 decays via electron-capture and generates photons with
prominent peaks in the 29 to 34-keV range [13]. Cs-131 seeds from
IsoRay Medical™ (Richland, WA) were utilized for all implants. Sources
contain a 4mmgoldmarker enclosedwith inorganic substrate adsorbed
with isotope (Fig. 1). Titanium capsules of thickness 0.05mmencase the
source and are welded at each end. Implant diameter and physical
source length are 0.84 mm and 4.5 mm respectively.
Dosemodeling for Cs-131was conceptually based on approximation
from the use of Au-198, based on investigator experience and theFig. 1. Schematic diagram of Cs-131 permcomparable low-dose rate (LDR) proﬁle. Cs-131 and Au-198 share com-
parable initial dose rates for commonly used prescription doses, there-
fore, it would be anticipated that Cs-131 would produce a similar
radiobiologic effect. However, a conversion factor of 1.1 (for Au-198 to
Cs-131) was used in almost all implants based on RBE assumptions,
equivalency calculations and the clinical observations and judgment of
one of the authors (MER) with extensive experience with permanent
seed implants. A sample dose calculation is presented in Appendix A.
A more extensive explanation of the calculation of our dose modeling
and conversion has been accepted and is pending publication in a sepa-
rate journal [16].
Implantation technique
Implant preplanning was based on tumor dimensions and shape.
Doses were most commonly calculated and prescribed to a depth of
5 mm using Paterson-Parker planar implant rules, although volume
implant calculations were also used as necessary. The total activity in
Au-198 (air-kerma strength) was calculated and then converted using
a factor of 1.1 for Cs-131 as stated above. All implants were performed
as outpatient procedures. A common premedication regimen included
a combination of 50 mg IM Meperidine, 25 mg IM Promethazine and
5–10 mg PO diazepam, but in some cases oral diazepam as a single
agent sufﬁced. Patients were placed in the dorsal lithotomy position
and a Foley catheter was placed with 7 cm3 of iodinated contrast per
International Commission on Radiation Units & Measurements recom-
mendations [17]. Patients received local anesthesia with inﬁltration of
2% lidocaine with epinephrine immediately prior to seed placement.
Seeds were placed individually by trocars. The exposure rate was
measured by a physicist at both the skin surface and at 1 m following
implantation. Veriﬁcation of seed distribution is most commonly per-
formed using orthogonal kV imaging (Fig. 2). An additional CT image
dataset was obtained in select patients with complex treatment vol-
umes to further assist in implant evaluation. Patients were discharged
home within a two hour recovery period with instructions per state
guidelines, providing the exposure rate was below 6 mR/h at 1 m.
Follow-up
All patients received follow-up in our radiation oncology depart-
ment within one month following implant and most commonly every
2–3 months afterwards. Response, local control and failureswere all de-
ﬁned by pelvic exam, imaging and biopsy when indicated. Local control
was deﬁned as no clinical evidence of tumor contained within and im-
mediately adjacent to the implanted area. Local control was calculated
according to total number of implants performed.
Regional failures were deﬁned as cancer outside of the implanted
area, including regional lymph nodes. Development of a separate
tumor in the vagina apart from the implanted and immediately adjacent
area was considered a regional failure. Distant failures were deﬁned as
metastatic disease. Both regional and distant failures are reported in
terms of patients treated. Early and late toxicities were scored andanent interstitial implant utilized.
Fig. 2. Orthogonal kV imaging used in post-plan analysis of Cs-131 permanent interstitial implant. Anteroposterior (A) and lateral (B) ﬁlms of a patient treated with 40 Gy to a single 3 ×
4 cmplane implant following45GyEBRT to a posterior vaginal wallmelanoma. All seedswere identiﬁed, and the corresponding isodose lineswere super-imposeddirectly onto the image.
The black line has been added to highlight the 4000 cGy isodose line.
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Events version 4.0.
Statistics
Cumulative doses delivered including external beamRT and brachy-
therapy were calculated using equivalent dose at 2 Gy per fraction with
α/β= 10 Gy using EQD2 per Groupe Européen de Curiethérapie (GEC)
and the European Society for Radiotherapy & Oncology (ESTRO) guide-
lines [18]. All statistics were performed by GraftPad Prism 6 (La Jolla,
CA). Analysis of differences between total tumor dose and local recur-
rence were analyzed using independent samples t-test and Fisher's
exact test with a preset p value of b0.05. Independent sample t-test
and Fisher's exact test were also used to associate tumor volume with
development of regional disease. Actuarial local control rates were cal-
culated using Kaplan–Meier statistics.
Results
Implantation characteristics
A total of 14 patients were identiﬁed among whom 17 Cs-131
permanent implants were performed (Tables 1 and 2). Patients had
biopsy-proven recurrent endometrial adenocarcinoma (n = 5), recur-
rent endometrial papillary carcinoma (n = 1), recurrent fallopian tube
adenocarcinoma (n = 1), recurrent cervical squamous cell carcinoma
(n = 2), recurrent vaginal melanoma (n = 1), primary cervical
adenosquamous/glassy cell carcinoma (n = 1), primary vaginal squa-
mous cell carcinoma (n = 1), primary vaginal melanoma (n = 1) and
primary clear cell endometrial carcinoma (n = 1). Histologic grade
was relatively high, as 54.6% and 27.3% of patients had grade III and
grade II diseases, respectively.
Ages ranged from 36 to 92 years with a median age of 65 years. For
the 10 patients treated for recurrent cancers, the median disease free
interval following initial curative-intent treatment was 18 months
(range 5–70 months). Previous treatment modalities for the 10 recur-
rent patients included: 4 received surgery/radiation/chemotherapy, 4
received surgery alone, 1 received radiation combined with surgery
and 1 received radiation alone. Preceding treatment modalities for
patients with primary cancers included: 1 with radiation/surgery, 1
with chemotherapy/surgery and 1 with surgery alone. Twelve patients
underwent implantation of a single lesion, 2 patients underwent im-
plantation of 2 separate lesions with one of these receiving a third im-
plant for persistent disease (Fig. 3). Sixteen planar implants and a
single two plane implant were performed.Permanent interstitial implants were performed as either the deﬁn-
itive RT modality, or as a supplemental boost following some combina-
tion of pelvic external beam RT with/without HDR brachytherapy
(Fig. 3). Seven implants were performed as deﬁnitive therapy, with a
median dose of 50 Gy delivered (range 33–75 Gy). Ten implants were
performed as a boost, with a median implant dose of 27.5 Gy (range
16.5–49.5 Gy). The median cumulative dose of radiation therapy pre-
ceding interstitial boost was 42.6 Gy (range 22.9–67.2 Gy), such that
median total tumor dosewas 78.25Gy (range 44.4–93.0 Gy). All perma-
nent implantswere performed following completion of pelvic RT and/or
HDR brachytherapy, with the exception of one patient with a vaginal
melanoma who received an upfront permanent interstitial implant to
the gross disease, followed by limited ﬁeld external RT. The average
and median volumes of the prescription isodose were 6.83 cm3 and
6.00 cm3 respectively, with a range of 1.77–17.5 cm3. The median num-
ber of Cs-131 sources used was 15 (range 7–25). Median and average
activity of sources were 1.39 U and 1.35 U (range 0.49–2.34 U).Treatment response
Median follow upwas 12 months (range 5–27 months) and the ob-
served local control rate was 88.2% (15/17) for all implants. Actuarial
local control at 12 months was estimated to be 84.4% (Fig. 4). Two
local failures occurred 5 and 7 months after the implant. One failure in-
cluded an isolated vaginal recurrence of fallopian tube adenocarcinoma
(after extensive prior treatment including aggressive external and intra-
cavitary RT) treated with a 33 Gy implant to a volume of 3.14 cm3. Re-
growth of the tumor was demonstrated 7 months following the
implant. Local control was obtained through reimplantation to 45 Gy
bringing total tumor dose to 78 Gy. The second local failure was a vagi-
nal recurrence from a previously treated endometrioid adenocarcino-
ma. She received a permanent interstitial brachytherapy implant in
combination with external beam radiation therapy to a total tumor
dose of 44.4 Gy to a volume of 17.5 cm3. Local recurrence and regional
lymph node failure were documented on a physical exam 5 months fol-
lowing her procedure. She remains alive at 15 months.
Three womenwere treated palliatively for symptomatic local recur-
rences in the setting of known regional and distant disease at the time of
implant. These patients had documented local control at their last
follow-up but progressed systemically and died due to distant disease,
as expected. For all patients treated with permanent interstitial im-
plants, 71.4% (10/14) were alive with no evidence of disease at last
follow-up. If one excludes the three patients treated with palliative in-
tent due to known metastatic disease, 10/11 patients (91%) remain
Table 1
Radiation dose characteristics by patient.
Patient
#
Volume
(cm3)
DFIa
(months)
Prior radiation therapy
EBRT brachytherapy
(Gy/fx)
Cs-131
dose (Gy)
Total tumor
treatment
dose (Gy)b
Total dose
to treated
area (Gy)c
Local
control
Regional
control
Follow-up
(months)
Toxicities
(graded —
system)
Primary tumors
Deﬁnitive implants 1 9.62 – 45/25 25/5 to point A with HDRe 55 55 55 Yes Yes 16 3 —mucosal
Boost implants 2 6.00 – – – 16.5 79.5 79.5 Yes Yes 13 1 —mucosal
3 7.85 – – – 40 84.3 84.3 Yes Yes 5 1 —mucosal
4 2.00 – – – 30 59.8 59.8 Yes Yes 8 2 —mucosal
Recurrent tumors
Deﬁnitive implants 5 9.00 9 45/25 25/5 to point A with HDR 75 75 75 Yes No 2 2 —mucosal
1 — dysuria
6f 3.00 15 45/25 20/4 to 5 mmwith HDR 45 75 114.3 Yes Yes 27 1 —mucosal
7f 2.00 46 42.5/25 33/2 to point A with LDR 50 50 93.1 Yes Yes 12 1 —mucosal
Boost implants 8 6.00 27 – – 22 85.0 85.0 Yes Yes 6 1 —mucosal
9 9.6 5 – – 49.5 82.0 82.0 Yes Yes 13 1 —mucosal
1 — dysuria
10 17.5 70 50.4/28 – 22 44.4 94.0 No No 15 1 —mucosal
11 15.0 13 45/25 – 45 77.0 77.0 Yes No 23 2 —mucosal
12 6.00 8 – – 30 93.0 93.0 Yes Yes 5 1 —mucosal
13 15.9 20 39.6/22 – 25 51.0 89.9 Yes No 12 1 —mucosal
1 — dysuria
14 2.00 55 – – 22 51.8 51.8 Yes Yes 9 1 —mucosal
Abbreviations: DFI = disease free interval; fx = fraction; EBRT = external beam radiation therapy; Cs = Cesium; HDR = high-dose rate; LDR = low-dose rate.
a Deﬁned as time from date completion prior treatment to biopsy proven recurrent tumor.
b Combined treatment dose to tumor including Cs-131 implant with external beam radiation and/or brachytherapy calculated using EQD2.
c Cumulative estimated dose to the treated area from contributions of previous radiation therapy and total tumor treatment dose.
d Grade based on Common Terminology Criteria for Adverse Events version 4.0.
e Previously treated cervical cancer with new vaginal primary.
f Patients treated with multiple Cs-131 interstitial implants; refer to Table 2.
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(range 5–27 months).
A multi-variate analysis of predictive patient and pathologic charac-
teristics was not performed due to the small sample size. However, it
was observed among our patient cohort that the only two local failures
occurred following a total treatment dose of b45Gy. Thiswas signiﬁcant
with a two-tailed Fisher's exact test (p = 0. 0058). One of these two
local failures was in the largest implant performed, at 17.5 cm3. The de-
velopment of regional disease at the time of implant or during follow-up
was associated with tumor size of ≥9 cm3, which was also signiﬁcant
with a two-tailed Fisher's exact test (p = 0.001).
Complications
All patients developed expected local and self-limited grade 1 and 2
post implant mucosal reactions. An early patient in this series was
treated to the highest deﬁnitive implant dose (75 Gy to a recurrent cer-
vical cancer which developed on the unirradiated vulva) resulting in a
brisk moist desquamation greater than expected based on an assumed
“Au-198 equivalent” of 60Gy. Thiswas empiric evidence that supported
modiﬁcation of the calculated conversion factor from 1.25 down to 1.1.
Two patients were described as having a superﬁcial necrosis involving
the vaginal mucosa, which was self-limited and resolved within an ap-
propriate post-implant period. Both were treated with deﬁnitive im-
plants to dose of 55 Gy and 50 Gy and previously received radiation toTable 2
Radiation dose characteristics of additional Cs-131 implants following initial implant by patien
Patient # Implant # Volume
(cm3)
Indication Cs-131
dose (Gy)
To
tre
do
6 2 3.14 Regional vaginal recurrence 33 33
6 3 1.77 Partial response to implant #2 45 78
7 2 3.14 Separate vaginal recurrence 50 50
a Combined treatment dose to tumor including Cs-131 implant with external beam radiatio
b Cumulative estimated dose to the treated area from contributions of previous radiation th
c Grade based on Common Terminology Criteria for Adverse Events version 4.0.BED of 83.2 Gy and 43.1 Gy respectively. Three patients experienced
self-limited dysuria following implantation of anterior vaginal wall. No
patients experienced signiﬁcant late toxicity secondary to Cs-131 inter-
stitial implants based on history and physical exam. Speciﬁcally, inci-
dence of ﬁstulas was 0% as was vaginal stenosis. No other instances of
bladder toxicity or rectal toxicity were observed following implants.
No hospitalizations or any other severe side effects occurred.Discussion
This study is theﬁrst to investigate Cs-131 permanent interstitial im-
plants for recurrent or new primary gynecologic malignancies.
Observed local control rate at time of analysis was 88.2%, exceeding
other published rates between 33 and 63% [8,10,11,19]. There are sever-
al factors that possibly explain these results. First, some patients are still
relatively early in the follow-up period. Second, some implants were
done as part of primary therapy as opposed to exclusively recurrent dis-
ease as in some series. Lastly, some patients received combined radia-
tion modalities with the Cs-131 implant used as a boost. As a result, it
is reasonable to expect that our local control rates might be favorable
compared to a series composed exclusively of recurrent tumors treated
with permanent interstitial brachytherapy alone. Therefore, actuarial
local control of 84.4% is suggested as a more accurate estimate of local
control.t.
tal tumor
atment
se (Gy)a
Total dose
to treated
area (Gy)b
Local
control
Regional
control
Follow-up
(months)
Toxicities
(gradec — system)
102.30 No Yes 19 1 —mucosal
147.30 Yes Yes 13 1 —mucosal
93.10 Yes Yes 6 3 —mucosal
n and brachytherapy calculated using EQD2.
erapy and total tumor treatment dose.
Fig. 3. Flow diagram for treated patients (refer to Tables 1 and 2 to reference patient numbers). Abbreviations: Cs= cesium; NED=no evidence of disease; loc/reg= local–regional. * Pa-
tient treated for 2 separate tumors. † Patient treated for 2 separate tumors with third additional implant for partial response. ‡ Patients treated palliatively with known regional and met-
astatic disease at implant and expired from distant disease progression despite durable local control.
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tumor dose and size of tumor, respectively. The only two local failures
in this series occurredwith a total tumor dose of b45 Gy, and all tumors
receiving ≥45 Gy maintained local control. The local failure treated to
33 Gy (in a re-irradiation setting) obtained local control through reim-
plantation with Cs-131 to 45 Gy, bringing total tumor dose from
Cs-131 to 78 Gy. Although statistically signiﬁcant, these associations
must be taken with caution due to the relatively small number of im-
plants to date and the limited number of observed failures. However,
the association of local failures and doses of b45 Gy is consistent with
previously published data [8,11].
Although comparable to other published series, this study is novel in
reporting the early clinical results of a new isotope previously unused in
gynecologic malignancies. This series documents themethodology, fea-
sibility, efﬁcacy and safety of Cs-131 permanent interstitial implants for
selected primary and recurrent gynecologic malignancies. Permanent
interstitial irradiation has a deﬁnite role in selected, accessible, small
volume gynecologic cancers. Previously reported favorable results
have been reconﬁrmed by our present study utilizing a new, safer
isotope. Permanent Cs-131 interstitial implants are relatively easy to
perform and can be used as a safe, effective and potentially curativeFig. 4. Local control by Kaplan–Meier following Cs-131 implants.option in patients with primary disease and in those with locally recur-
rent disease, whether or not the patient has had previous RT. This cura-
tive option should be more frequently and widely incorporated into
gynecologic oncology and radiation oncology practice, especially as ex-
perience increases and as clinical data continues to mature.
Conﬂict of interest statement
The authors have no conﬂicts of interest in this research or manuscript preparation.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygyno.2014.02.015.
References
[1] American Cancer Society. Cancer facts & ﬁgs. 2012. Atlanta, GA: American Cancer
Society; 2012.
[2] Lawhead Jr RA, Clark DG, Smith DH, Pierce VK, Lewis Jr JL. Pelvic exenteration for re-
current or persistent gynecologic malignancies: a 10-year review of the Memorial
Sloan–Kettering Cancer Center experience (1972–1981). Gynecol Oncol 1989;33:
279–82.
[3] Berek JS, Howe C, Lagasse LD, Hacker NF. Pelvic exenteration for recurrent gyneco-
logic malignancy: survival and morbidity analysis of the 45-year experience at
UCLA. Gynecol Oncol 2005;99:153–9.
[4] Jhingran A, Burke TW, Eifel PJ. Deﬁnitive radiotherapy for patients with isolated vag-
inal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol
Phys 2003;56:1366–72.
[5] Beriwal S, Bhatnagar A, Heron DE, Selvaraj R, Mogus R, Kim H, et al. High-dose-rate
interstitial brachytherapy for gynecologic malignancies. Brachytherapy 2006;5:
218–22.
[6] Monk BJ, Walker JL, Tewari K, Ramsinghani NS, Nisar Syed AM, DiSaia PJ. Open inter-
stitial brachytherapy for the treatment of local–regional recurrences of uterine
corpus and cervix cancer after primary surgery. Gynecol Oncol 1994;52:222–8.
[7] Nag S, Yacoub S, Copeland LJ, Fowler JM. Interstitial brachytherapy for salvage treat-
ment of vaginal recurrences in previously unirradiated endometrial cancer patients.
Int J Radiat Oncol Biol Phys 2002;54:1153–9.
[8] Randall ME, Evans L, Greven KM, McCunniff AJ, Doline RM. Interstitial reirradiation
for recurrent gynecologic malignancies: results and analysis of prognostic factors.
Gynecol Oncol 1993;48:23–31.
[9] Tewari K, Cappuccini F, Brewster WR, DiSaia PJ, Berman ML, Manetta A, et al. Inter-
stitial brachytherapy for vaginal recurrences of endometrial carcinoma. Gynecol
Oncol 1999;74:416–22.
273C.E. Wooten et al. / Gynecologic Oncology 133 (2014) 268–273[10] Chung JY, Roberts K, Peschel RE, Nath R, Pourang R, Kacinski B, et al. Treatment of
recurrent pelvic and selected primary gynecologic malignancies with 241Am. Radiat
Oncol Investig 1997;5:227–34.
[11] Brabham JG, Cardenes HR. Permanent interstitial reirradiation with 198Au as
salvage therapy for low volume recurrent gynecologic malignancies: a single institu-
tion experience. Am J Clin Oncol 2009;32:417–22.
[12] Bice WS, Prestidge BR, Kurtzman SM, Beriwal S, Moran BJ, Patel RR, et al. Recom-
mendations for permanent prostate brachytherapy with 131Cs: a consensus report
from the Cesium Advisory Group. Brachytherapy 2008;7:290–6.
[13] Murphy MK, Piper RK, Greenwood LR, MitchMG, Lamperti PJ, Seltzer SM, et al. Eval-
uation of the new cesium-131 seed for use in low-energy X-ray brachytherapy. Med
Phys 2004;31:1529–38.
[14] Parashar B, Wernicke AG, Pavese A, Singh P, Trichter S, Sabbas A, et al. Cesium-131
permanent seed brachytherapy: dosimetric evaluation and radiation exposure to
surgeons, radiation oncologists, and staff. Brachytherapy 2011;10:508–13.[15] Armpilia CI, Dale RG, Coles IP, Jones B, Antipas V. The determination of radiobiolog-
ically optimized half-lives for radionuclides used in permanent brachytherapy
implants. Int J Radiat Oncol Biol Phys 2003;55:378–85.
[16] Luo W, Molloy J, Aryal P, Feddock J, Randall M. Determination of prescription dose
for Cs-131 permanent implants using the BED formulism including resensitization
correction. Med Phys 2014:41.
[17] International Commission on Radiation Units and Measurements (ICRU) (ICRU).
Dose and volume speciﬁcation for reporting intracavitary therapy in gynecology.
ICRU Report, 38Bethesda, MD: ICRU; 1985.
[18] Calculating biological doses. learn eXact v4.0; 2013.
[19] Okazawa K, Yuasa-Nakagawa K, Yoshimura R, Shibuya H. Permanent interstitial re-
irradiation with Au-198 seeds in patients with post-radiation locally recurrent uter-
ine carcinoma. J Radiat Res 2013;54:299–306.
